跳至主要内容
临床试验/ACTRN12624000763549
ACTRN12624000763549尚未招募Unknown

A Randomised Controlled Trial Assessing the Efficacy of Intra-operative Rigenera Autologous Micrograft Therapy (AMT) on graft survival, hair follicle density and thickness in FUT Hair Transplant Patients vs placebo

Dr Adam Ellerby0 个研究点目标入组 40 人开始时间: 2024年6月21日最近更新:
适应症

试验速览

阶段
Unknown
状态
尚未招募
发起方
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
25 Years 至 o limit(—)
性别
All

入选标准

  • Forty patients aged over 25 undergoing FUT hair transplant for androgenetic alopecia (AGA).
  • Patients selected based on their need for frontal region transplant
  • Frontal recipient area must have advanced AGA
  • Medications - Every patient should be stabilised on hair loss medications (ie slow progression or cessation of hair loss for >6 months using standard medical therapies)

排除标准

  • Non-androgenic cause for alopecia - autoimmune, scaring, thyroid, iron and vitamin D deficiencies.
  • Previous hair transplant surgery within past 18 months
  • Other regenerative treatments within past 12 months - Rigenera, Platelet rich plasma (PRP), Platelet rich fibrin (PRF)
  • Inter-current systemic illness or scalp disease - Human immunodeficiency virus (HIV), Hepatitis, cancer, haematological disease, fungal scalp, dermatitis
  • Interstate or out of area patients due to in-person follow up requirements - New South Wales (NSW) patients only

研究者

发起方
Dr Adam Ellerby

相似试验